AVGR Earnings

AVGR reported its FY2024Q1 earnings on 2024-05-15, showcasing a revenue of 1.86M against an estimate of 2.36M, resulting in a -21.23% surprise. The EPS was -2.49, surpassing the expected -1.35 by -84.44% . The stock experienced a -0.26% price change on the earnings day and a -23.38% change over the next five days, reflecting market reactions to the results.

Following AVGR's FY2024Q1 earnings announcement on 2024-05-15, the stock price moved by -0.26% on the day of the release. Over the subsequent five days, it saw a -23.38% change. Historically, AVGR's stock price tends to shift by an average of +3.28% in the 10 days leading up to earnings and -13.78% in the 10 days following, providing insight into potential market.

For 2024/Q4, analysts estimate AVGR’s annual revenue to reach 1.86M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AVGR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2024 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AVGR's stock price typically moves by +3.28% in the 10 days before its earnings and -13.78% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of undefined and revenue of 1.86M.

The earnings call presents a mixed picture. While there are positives like improved gross margins and a strategic partnership with Zylox, revenue has slightly declined, and significant risks remain, such as regulatory challenges and competitive pressures. The Q&A session reveals optimism about product reception but also highlights uncertainties in the partnership with Zylox. With no announced shareholder return plans and ongoing financial challenges, the stock price is likely to remain stable, resulting in a neutral sentiment.